Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Stefania Gori, Massimo Barberis, Maria Angela Bella, Fiamma Buttitta, Ettore Capoluongo, Paola Carrera, Nicoletta Colombo, Laura Cortesi, Maurizio Genuardi, Massimo Gion, Valentina Guarneri, Lorena Incorvaia, Nicla La Verde, Domenica Lorusso, Antonio Marchetti, Paolo Marchetti, Nicola Normanno, Barbara Pasini, Matilde Pensabene, Sandro PignataPaolo Radice, Enrico Ricevuto, Anna Sapino, Pierosandro Tagliaferri, Pierfrancesco Tassone, Chiara Trevisiol, Mauro Truini, Liliana Varesco, Antonio Russo, AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group

Research output: Contribution to journalArticle

Abstract

The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).
Original languageUndefined/Unknown
Pages (from-to)67-72
Number of pages6
JournalCritical Reviews in Oncology/Hematology
Volume140
DOIs
Publication statusPublished - Aug 1 2019

Keywords

  • BRCA1 Protein
  • genetics
  • BRCA2 Protein
  • Biochemistry
  • Female
  • Genetic Testing
  • standards
  • Genetics
  • Germ-Line Mutation
  • Humans
  • Italy
  • Medical Oncology
  • Ovarian Neoplasms
  • diagnosis
  • Societies
  • Medical
  • BRCA1
  • BRCA2
  • Genetic testing
  • Germline mutations
  • Ovarian cancer
  • PARP inhibitors
  • Somatic mutations

Cite this

Gori, S., Barberis, M., Bella, M. A., Buttitta, F., Capoluongo, E., Carrera, P., ... Group, AIOM-SIGU-SIBIOC-SIAPEC-IAP. W. (2019). Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Critical Reviews in Oncology/Hematology, 140, 67-72. https://doi.org/10.1016/j.critrevonc.2019.05.012